Clinical Trial Update: A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ATG-010 for safety and efficacy in relapsed/refractory diffuse large B-cell lymphoma has completed, with results posted on 2025-02-07.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• ATG-010

Snippet

Sponsor: Antengene Corporation | Conditions: Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Status: COMPLETED | Results posted: 2025-02-07